Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

Analyst Ratings

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (?)
Ratings Breakdown: 5 Sell Rating(s), 6 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Hold (Score: 2.11)
Consensus Price Target: $24.71 (3.42% upside)

Analysts' Ratings History for Sarepta Therapeutics (NASDAQ:SRPT)
Show:
DateFirmActionRatingPrice TargetActions
7/22/2016Needham & Company LLCBoost Price TargetBuy$20.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/19/2016WedbushReiterated RatingOutperform$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/19/2016Cowen and CompanyReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/18/2016Robert W. BairdReiterated RatingOutperform$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/27/2016William BlairReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2016Jefferies GroupReiterated RatingUnderperform$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Piper Jaffray Cos.UpgradeUnderweight -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016WBB SecuritiesReiterated RatingBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Janney Montgomery ScottReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016Royal Bank Of CanadaReiterated RatingHold$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016Leerink SwannReiterated RatingUnderperform$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016JMP SecuritiesReiterated RatingSell$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/27/2016SunTrust Banks Inc.Reiterated RatingReduceView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Ladenburg ThalmannDowngradeMarket Perform -> Underperform$13.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/8/2015Roth CapitalReiterated RatingBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/23/2015Bank of America Corp.Initiated CoverageBuy$49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/1/2015SusquehannaBoost Price TargetNeutral$33.00 -> $36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Deutsche Bank AGReiterated RatingHold$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015Canaccord GenuityUpgradeHold -> Buy$16.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2015Northland SecuritiesUpgradeMarket Perform -> Outperform$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2014Stifel NicolausDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/7/2014Credit Suisse Group AGReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Sarepta Therapeutics (NASDAQ:SRPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
7/19/2016Q2($1.19)($1.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2016Q1($1.30)($1.15)$0.18 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2016Q4($1.18)($1.30)$1.25 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($1.19)($1.25)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($1.21)($1.01)$0.31 million$0.01 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($1.00)($1.49)$0.78 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q414($0.82)($0.94)$1.56 million$0.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.96)($0.70)$3.07 million$1.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.76)($0.85)$4.30 million$2.58 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.80)($0.75)$3.45 million$6.09 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413($0.69)($0.77)$4.53 million$2.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q313($0.65)($0.63)$4.57 million$4.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.67)($0.46)$5.08 million$3.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.62)($0.41)$5.85 million$4.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2013Q4 2012($0.26)($2.36)$6.71 million$7.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012($0.27)($2.17)$10.06 million$7.57 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sarepta Therapeutics (NASDAQ:SRPT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.40)($1.17)($1.29)
Q2 20165($1.32)($0.62)($1.08)
Q3 20166($1.19)($0.59)($0.93)
Q4 20166($1.00)($0.47)($0.76)
Q1 20171($0.68)($0.68)($0.68)
Q2 20171($0.60)($0.60)($0.60)
Q3 20171($0.49)($0.49)($0.49)
Q4 20171($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sarepta Therapeutics (NASDAQ:SRPT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sarepta Therapeutics (NASDAQ:SRPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/16/2016M Kathleen BehrensDirectorBuy10,000$14.54$145,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016M Kathleen BehrensDirectorBuy65,000$16.54$1,075,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2013Anthony ChaseDirectorBuy10,000$13.95$139,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013M Kathleen BehrensDirectorBuy6,500$37.04$240,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013John HodgmanDirectorSell5,556$34.97$194,293.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2013Anthony ChaseDirectorBuy3,500$32.68$114,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Sandesh MahatmeCFOBuy5,000$31.10$155,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2013Anthony R ChaseDirectorBuy10,000$38.50$385,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/7/2012M Kathleen BehrensDirectorBuy17,500$14.73$257,775.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sarepta Therapeutics (NASDAQ:SRPT)
DateHeadline
07/23/16 10:21 AMSarepta Therapeutics Inc. (SRPT) Jumps 5.47% on July 22 - Equities.com
07/22/16 06:23 PMAnalyst Update: athenahealth, Inc, Adeptus Health Inc, and Sarepta Therapeutics Inc
07/22/16 09:28 AMAnalyst Rating Trends to Observe: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) , Baxter International Inc. (NYSE:BAX) - Street Updates
07/22/16 09:28 AMBroker Outlook For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Fiscal Standard
07/22/16 09:28 AMPrice Target Spotlight: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - News Oracle
07/22/16 09:28 AMSarepta Therapeutics Inc. (SRPT) Jumps 6.24% on July 20 - Equities.com
07/22/16 09:28 AMJMP Securities Chimes In on Sarepta Therapeutics Inc (SRPT) Following 2Q Update; Awaits FDA Decision on Eteplirsen - Smarter Analyst
07/21/16 06:53 PMSRPT Makes Bullish Cross Above Critical Moving Average
07/21/16 10:02 AMWhy Investors Flocked to Sarepta Therapeutics This Week -
07/20/16 07:32 PMWedbush Upgrades Rating On Sarepta Therapeutics, Inc. (SRPT) - Finance Daily
07/20/16 07:32 PMAnalyst's Focused Stocks Endo International (ENDP) , Sarepta Therapeutics, Inc. (SRPT) - Street Updates
07/20/16 07:32 PMCowen Weighs In on Sarepta Therapeutics Inc (SRPT) in Light of More Regulatory Setbacks in DMD Field - Smarter Analyst
07/20/16 09:30 AMSarepta Therapeutics : reports 2Q loss
07/20/16 09:30 AMSarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate Developments
07/20/16 08:47 AMSarepta Therapeutics (SRPT) Stock Falls on Q2 Earnings Loss -
07/20/16 07:57 AMSarepta (SRPT) Posts Y/Y Wider Q2 Loss, Eteplirsen in Focus -
07/19/16 03:06 PMSarepta Therapeutics reports 2Q loss -
07/19/16 07:33 AMEye Catching Stock for investors: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - News Oracle
07/19/16 07:33 AMOppenheimer Remains Positive on Sarepta Therapeutics Inc (SRPT) in Wake of Santhera FDA Rejection - Smarter Analyst
07/17/16 05:53 PMSarepta Therapeutics, Inc. (NASDAQ:SRPT) Earnings Review and Target Watch - TGP
07/17/16 10:35 AMNext Weeks Broker Price Targets For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Fiscal Standard
07/14/16 03:14 PMSarepta Stock Slides As FDA Sends Another Bad Signal On DMD -
07/14/16 11:50 AMIs There Hope for Sarepta? -
07/14/16 10:35 AMSarepta Therapeutics stock slumps 3.5% after other DMD drug is denied accelerated approval -
07/14/16 07:46 AMDuchenne Drug Developer (Not Sarepta) Hit With Lengthy FDA Delay -
07/13/16 06:55 PMHC Stocks in Front Line: Array Biopharma Inc (NASDAQ:ARRY), Sarepta Therapeutics Inc (NASDAQ:SRPT) - share market updates (press release)
07/13/16 09:27 AMBiotech news that matter for investors: Sarepta Therapeutics (SRPT), Relypsa (NASDAQ:RLYP) - The Voice Registrar
07/13/16 09:27 AMSarepta Therapeutics, Inc. (NASDAQ:SRPT): Updated Analyst Ratings - Review Fortune
07/13/16 09:27 AMMomentum Stocks: Sarepta Therapeutics, Inc. (SRPT), Radian Group Inc. (RDN), Franklin Resources, Inc. (BEN ... - iStreetWire
07/13/16 09:27 AMEye Catching Stock: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - News Oracle
07/13/16 09:27 AMSarepta Therapeutics Inc. (SRPT) Drops 5.53% on July 11 - Equities.com
07/12/16 04:26 PM3 Risky Biotech Stocks That Could Make You Rich - Acadia Pharmaceuticals, Amarin Corp. and Sarepta Therapeutics all have the potential to generate life-changing gains for risk-tolerant investors.
07/10/16 05:46 PMSarepta Therapeutics, Inc. (NASDAQ:SRPT): Check on Company Stock Performance - Press Telegraph
07/10/16 05:46 PMHow Analysts Rated Sarepta Therapeutics Inc (NASDAQ:SRPT) Last Week? - Engelwood Daily
07/09/16 09:37 AMSarepta Therapeutics, Inc. Stock Momentum at Critical Inflection Point - CML News
07/09/16 08:41 AMWhy Sarepta Therapeutics Shares Slipped 10.9% in June -
07/07/16 06:35 PM[$$] Boys, Not Statistics -
07/06/16 07:00 PMInsiders Increasing Positions in: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Press Telegraph
07/06/16 10:26 AMAnalysts Observing Stocks: Rock Creek Pharmaceuticals, Inc. (PNK:RCPI) , Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Street Updates
07/06/16 10:26 AMSarepta Therapeutics Inc. (SRPT) Jumps 6.19% on July 04 - Equities.com
07/05/16 10:49 AMAnalysts Spotlight: Novavax, Inc. (NASDAQ:NVAX) , Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Street Updates
07/04/16 05:38 PMStock Sentiment Watch for:Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Press Telegraph
07/04/16 05:38 PMMajor Move Is Coming For Sarepta Therapeutics Inc After Bullish Options Activity - Press Telegraph
07/02/16 06:01 PMTrade-Ideas: Sarepta Therapeutics (SRPT) Is Today's Post-Market Leader Stock - TheStreet.com
07/01/16 11:15 PM[$$] Where’s the Drug, FDA? -
07/01/16 05:47 PM[$$] Where's the Drug, FDA? -
07/01/16 03:25 PMSAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex -
07/01/16 09:15 AMYesterday's Attention Gainer: Sarepta Therapeutics Inc (NASDAQ:SRPT), Harley Davidson Inc (NYSE:HOG), Lincoln ... - iStreetWire
07/01/16 09:15 AMStock Performance to Track: Sarepta Therapeutics (SRPT) - News Oracle
06/29/16 06:29 PMSarepta Therapeutics, Inc. (NASDAQ:SRPT) Earnings Review and Target Focus - Telanagana Press

Social

About Sarepta Therapeutics

Sarepta Therapeutics logoSarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company's lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SRPT
  • CUSIP:
Key Metrics:
  • Previous Close: $22.65
  • 50 Day Moving Average: $19.63
  • 200 Day Moving Average: $18.21
  • P/E Ratio: N/A
  • P/E Growth: 24.15
  • Market Cap: $1.09B
  • Beta: 1.64
  • Current Year EPS Consensus Estimate: $-4.56 EPS
  • Next Year EPS Consensus Estimate: $-2.9 EPS
Additional Links:
Sarepta Therapeutics (NASDAQ:SRPT) Chart for Saturday, July, 23, 2016